You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Homologous Recombination deficiency (HRD)

Showing 1 - 25 of 3,695
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer Trial in Shanghai (Fluzoparib, Irinotecan)

Not yet recruiting
  • Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer
  • Shanghai, Shanghai, China
    Department of Colorectal Surgery Fudan University Shanghai Caner
Feb 22, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Guangzhou (Pamiparib)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Apr 7, 2022

Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Deficiency (HRD) Trial in Worldwide

Terminated
Has Results
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Homologous Recombination Deficiency (HRD)
  • Athens, Georgia
  • +8 more
Oct 20, 2021

HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

Completed
  • Epithelial Ovarian Cancer
  • +6 more
  • Evaluation of homologous recombination deficiency score
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

HRD and Resistance to PAPPi in EOC Patients

Recruiting
  • Epithelial Ovarian Cancer
  • +6 more
  • Testing of homologous recombination deficiency
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

Breast Cancer Trial in Spain (Olaparib)

Terminated
  • Breast Cancer
  • Barcelona, Spain
  • +7 more
Jan 18, 2023

Pancreatic Adenocarcinoma, Homologous Recombination Deficiency Trial (Cisplatin)

Not yet recruiting
  • Pancreatic Adenocarcinoma
  • Homologous Recombination Deficiency
  • (no location specified)
Oct 18, 2023

Homologous Recombination Deficiency in Chinese Ovarian Cancer

Not yet recruiting
  • Ovarian Cancer
  • +2 more
  • PARP inhibitor
  • Nanjing, Jiangsu, China
    Xiaoxiang Chen, MD,PhD
Sep 4, 2021

Ovarian Cancer Trial in Pittsburgh (Olaparib tablet)

Not yet recruiting
  • Ovarian Cancer
  • Olaparib tablet
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Nov 1, 2023

Mesothelioma, Homologous Recombination Deficiency Trial in Chicago (Olaparib)

Recruiting
  • Mesothelioma
  • Homologous Recombination Deficiency
  • Chicago, Illinois
    University of Chicago Medical Center
May 12, 2021

Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Recruiting
  • Lung Cancer
    • Shanghai, China
      Shanghai Chest Hospital
    Jul 20, 2023

    Homologous Recombination-related Genesmutationsand HRD in Breast

    Not yet recruiting
    • Breast Cancer
    • HER2-low Breast Cancer
    • Standard Management
    • Guangzhou, Guangdong, China
      Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    Jul 18, 2022

    Triple Negative Breast Cancer Trial in United States (Cisplatin, Paclitaxel)

    Active, not recruiting
    Has Results
    • Triple Negative Breast Cancer
    • Birmingham, Alabama
    • +19 more
    Feb 14, 2022

    A Training Set for the HRD Model in EOC

    Recruiting
    • Epithelial Ovarian Cancer
    • +5 more
    • Homologous recombination deficiency model
    • Beijing, Beijing, China
      Lei Li
    Dec 2, 2020

    Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer Trial in Guangzhou (Fluzoparib, Fluzoparib+Camrelizumab)

    Recruiting
    • Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
    • Guangzhou, Guangdong, China
      Sun-yat sen university cancer center
    Jan 27, 2023

    Advanced Solid Tumors Trial in Worldwide (Olaparib)

    Recruiting
    • Advanced Solid Neoplasms
    • Tucson, Arizona
    • +128 more
    Aug 18, 2022

    Homologous Recombination Inquiry Through Ovarian Malignancy

    Completed
    • Ovarian Cancer
    • +2 more
      • Niigata city, Niigata Prefecture, Japan
        Niigata University Graduate School of Medical and Dental Science
      Jan 19, 2023

      Homologous Recombination Deficiency, Triple Negative Breast Cancer Trial (Niraparib)

      Not yet recruiting
      • Homologous Recombination Deficiency
      • Triple Negative Breast Cancer
      • (no location specified)
      Jul 15, 2022

      Metastatic Colorectal Cancer Trial in Spain (Olaparib, Pembrolizumab)

      Not yet recruiting
      • Metastatic Colorectal Cancer
      • Sevilla, Andalucia, Spain
      • +14 more
      Aug 2, 2022

      Breast Cancer Trial in Amsterdam (carboplatin, thiotepa, and cyclophosphamide, chemo (docetaxel, doxorubicin, cyclofosfamide,

      Recruiting
      • Breast Cancer
      • carboplatin, thiotepa, and cyclophosphamide
      • chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)
      • Amsterdam, Netherlands
        NKI-AVL
      Mar 21, 2022

      HER2-negative Breast Cancer Trial in Chengdu (AT regimen, TP regimen)

      Unknown status
      • HER2-negative Breast Cancer
      • AT regimen
      • TP regimen
      • Chengdu, Sichuan, China
        Department of breast surgery, Sichuan Provincial People's Hospit
      Jul 30, 2020

      Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer Trial in Stanford (Talazoparib Tosylate)

      Active, not recruiting
      • Advanced Breast Cancer
      • +2 more
      • Talazoparib Tosylate
      • Stanford, California
        Stanford University Hospitals and Clinics
      Nov 16, 2022

      Homologous Recombination Deficiency Among Newly Diagnosed,

      Recruiting
      • Fallopian Tube Cancer
        • Arkhangelsk, Russian Federation
        • +24 more
        Jul 18, 2022

        HRD Cancer, SCLC, Advanced Solid Tumors Trial run by the NCI (Berzosertib, Sacituzumab Govitecan)

        Recruiting
        • HRD Cancer
        • +2 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Jan 20, 2023

        Solid Tumor, Adult Trial in Miami (Pembrolizumab 200 mg Q3W)

        Active, not recruiting
        • Solid Tumor, Adult
        • Pembrolizumab 200 mg Q3W
        • Miami, Florida
          Miami Cancer Institute at Baptist Health, Inc.
        Nov 18, 2022